Coronary Occlusions Clinical Trial
Official title:
AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study
Chronically total occlusions (CTO) are difficult to treat and have high risk for restenosis.
Although everolimus-eluting stents (EES) [(Xience, Abbott Vascular) or Promus (Boston
Scientific)] are very promising for the treatment of CTOs due to their low late loss and
excellent deliverability, there are currently no published data on EES implantation in CTOs.
The specific aim of this proposal is to examine the 8-month incidence of binary angiographic
in-stent restenosis (defined as a stenosis of > 50% of the minimum lumen diameter of the
target stent) after implantation of the EES in CTO.
It is the investigators hypothesis that EES-treated CTO lesions will have ≤ 20% 8-month
in-stent binary angiographic restenosis rate.
n/a
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00378612 -
ACROSS-Cypher Total Occlusion Study of Coronary Arteries 4 Trial
|
Phase 3 |